Sm p80
Alternative Names: SchistoShield; Sm-p80Latest Information Update: 23 Feb 2026
At a glance
- Originator Texas Tech University Health Sciences Center
- Developer National Institute of Allergy and Infectious Diseases; PAI Life Sciences
- Class Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Schistosomiasis
Most Recent Events
- 23 Feb 2026 Sm p80 is still in phase-I trial in Schistosomiasis (Prevention) in USA, Burkina Faso and Madagascar (IM)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Schistosomiasis(Prevention) in Burkina Faso (IM, Injection)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Schistosomiasis(Prevention) in Madagascar (IM, Injection)